AZD0364

AZD0364 (CAS No.: 2097416-76-5), also known as tizaterkib and ATG-017, is a synthetic small-molecule tool compound for kinase pharmacology and signal transduction research, primarily serving advanced research settings such as tumor-related discovery and target validation; its functional positioning is directed at extracellular signal-regulated kinases in the MAPK cascade, exhibiting high-affinity inhibition of ERK2 while also acting on ERK1, thereby supporting precise intervention and quantitative analysis of downstream pathway output and feedback regulation; in multi-target kinase profiling, it shows significant selectivity for ERK2 over the upstream kinase MEK1, with limited off-target effects and only a small number of kinases showing marked inhibition under the screening conditions; its in vitro activity overall falls within the sub-nanomolar to low-nanomolar range (for primary targets) and extends to the tens to hundreds of nanomolar level (for secondary targets), making it useful as a selective chemical probe for pathway mapping, signal feedback, and tolerance mechanism studies; at the application level, it is commonly used in cell models carrying MAPK pathway activation backgrounds and in animal models for validation of ERK pathway dependency, and may also be combined with MEK inhibitors to explore vertical pathway inhibition strategies, with the relevant treatment concentrations or doses typically optimized according to the specific experimental design and research objectives; in summary, AZD0364 provides highly selective and highly sensitive research support for elucidating ERK-driven signaling networks and adaptive reprogramming.